B. Riley Analysts Give Actinium Pharmaceuticals (ATNM) a $3.00 Price Target
B. Riley set a $3.00 price objective on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a report released on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other equities research analysts have also issued reports on the stock. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, November 14th. Roth Capital restated a buy rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, HC Wainwright restated a buy rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd.
Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.64 on Tuesday. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72.
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.